| For: | Mao QY, Ran H, Hu QY, He SY, Lu Y, Li H, Chai YM, Chu ZY, Qian X, Ding W, Niu YX, Zhang HM, Li XY, Su Q. Impaired efferocytosis by monocytes and monocyte-derived macrophages in patients with poorly controlled type 2 diabetes. World J Diabetes 2025; 16(5): 101473 [PMID: 40487610 DOI: 10.4239/wjd.v16.i5.101473] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v16/i5/101473.htm |
| Number | Citing Articles |
| 1 |
Yanqi Lei, Min Tang, Huilan Deng, Yanqun Li, Jidi Wu, Li Luo, Yulin Mou, Qianshi Wu, Qifu Li, Yong Xu, Wei Huang. Defective efferocytosis in diabetes: molecular mechanisms and emerging therapeutic strategies. Inflammation Research 2026; 75(1) doi: 10.1007/s00011-026-02302-w
|
| 2 |
Yi Song, Jiayi Yuan, Yifan Li, Yifan Liu, Guijun Qin. Efferocytosis: a therapeutic strategy for diabetes and its vascular complications. Frontiers in Cell and Developmental Biology 2025; 13 doi: 10.3389/fcell.2025.1641748
|
| 3 |
Dania Al‐Sharify, Jiangming Sun, Andreas Edsfeldt. The changing epidemiology of human type 2 diabetes–associated atherosclerosis: Pathophysiological mechanisms and emerging treatment possibilities. Journal of Internal Medicine 2026; 300(2) doi: 10.1111/joim.70118
|